Stockreport

Astria commences Phase III hereditary angioedema therapy trial [Yahoo! Finance]

Astria Therapeutics, Inc.  (ATXS) 
PDF The global, double-blind trial is designed to assess the safety and efficacy of the therapy over six months. It will evaluate navenibart in up to 135 adults and ten a [Read more]